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Skin 55 (40) 63 (45) 4 (3) 17 (12)
Mouth 70 (50) 64 (46) 4 (3) 1 (1)
Eyes 71 (51) 59 (42) - 9 (7)
GI tract 110 (79) 15 (11) 3 (2) 11 (8)
Liver 99 (71) 27 (19) 8 (6) 5 (4)
Lungs 97 (70) 18 (13) 3 (2) 21 (15)
Joint 97 (70) 32 (23) 3 (2) 7 (5)
Genital 123 (89) 10 (7) 2 (1) 4 (3)
Figure. Distribution of global severity scores according to NIH chronic GVHD
consensus criteria with and without confounders
Figure 1. Engraftment of human cells in NSG mice
Lung or liver from NSG mice 8 weeks post transplantation were examined for
human CD4, CD8, CD20 and CD68 engraftment by IHC. Three randomly
selected sections per slide were observed under the x40 objective. Data were
calculated as: % positive cells ¼ positive nuclei cells Ú total cells nuclei x 100.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S257eS285S266the abnormalities is shown in the Table. Abnormalities not
attributed to chronic GVHD were observed most frequently
in lungs, gastrointestinal tract and skin sites. The most
common causes of abnormalities attributed to other causes
than GVHD included: conditions prior to the transplant,
sequela from prior GVHD, deconditioning, infections and
medications. When scores for organs or sites with abnor-
malities attributed to other than chronic GVHD were
rescored as zero, the global severity score shifted downward
from mild (n¼7), moderate (n¼2), and severe (n¼1) to none
and from moderate (n¼8) and severe (n¼1) to mild (Figure).
Conclusion: A modest downward shift of the global severity
score occurs when confounders are taken into account in the
0-3 organ-speciﬁc scoring system. Our ﬁndings support the
need for clariﬁcation of the NIH diagnosis and staging
consensus criteria.414
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PBMCs can develop xenogeneic acute graft-versus-host dis-
ease (aGVHD), which mimics human aGvHD manifestations,
including skin or liver involvement. In contrast little is
known about the chronic GVHD (cGVHD) mouse model,
although a recently described humanized cGVHD model
using NSG mice with human thymocytes showed liver
ﬁbrosis 14 weeks after transplantation. Here, we established
a humanized cGVHDmodel with chronic lung inﬂammation
and ﬁbrosis mimicking human cGvHD 8 weeks post
transplantation.
Material and Method: NSGmicewere recipients and treated
with cyclophosphamide (Cy) at different doses (20-120mg/
kg) at day -3 and -2 plus 200cGy X-ray at day-1 followed by
injection of 1-5x106 G-CSFmobilized human PBMCs or 1x105
CD34+ cells at day 0. Samples of skin, lung, liver, spleen and
small intestine were taken 8 weeks post transplantation, and
ﬁxed in 10% neutral-buffered formalin, embedded in parafﬁn,
sectioned, slide mounted, and stained with hematoxylin and
eosin and Masson’s trichrome. Specimens were evaluated
blinded by a pathologist. Engraftment was assessed in pe-
ripheral blood by ﬂow cytometry and in each organ by
immunohistochemistry (IHC) using anti-human CD4/8/20/
68 antibodies.
Result: Mice that received over 60mg/kg of Cy lost weight
and died earlier than those receiving 20mg/kg or less. Sub-
sequently we used 20mg/kg Cy combinedwith 200cGy TBI as
conditioning for the study. Mice receiving 5x106 PBMCs
exhibited acute illness including hunching or rufﬂed hair and
died earlier compared with mice receiving 1x106PBMCs. IHC
analysis revealed engraftment of CD4, CD8 T cells, CD20+ B
cells but not CD68+ cells in the lung, liver, skin or spleen
(Figure 1). Analysis at 8 weeks post-transplantation showed
that themice receiving 1x106PBMCs exhibited aggregation of
Figure 2. Lung ﬁbrosis in NSG mice 8 weeks after transplantation
The lung from NSG mouse bearing PBMCs (A) or CD34+ cells (B) 8 weeks after transplantation was stained with Masson’s trichrome. Fibrosis is shown in blue.
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airways in the lung despite showing no sign of acute illness
or weight loss. Masson’s trichrome revealed increased
ﬁbrosis in the lung (Figure 2), but not in other organs.
Conclusion: We have shown that in the NSG mouse, a
combination of Cy/TBI with a lownumber of G-CSFmobilized
human PBMCs causes chronic lung inﬂammation and ﬁbrosis
that can serve as an important pre-clinic model of lung
cGVHD.415
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Introduction: Transplants from cord blood stem cells is
known to have lower incidence of graft-versus-host disease
(GVHD). However, in patients who undergo cord blood
transplant (CBT) and develop GVHD, its features are not well
studied.
Objectives: Determine clinical features of GVHD and dura-
tion of therapy in patients who received CBT.
Patients and Methods: From 1993 to 2013, 196 patients
received CBT were retrospectively analised and divided into
two categories. Group 1: 64 patients who developed GVHD.
Group 2: 132 patients without this complication. Acute
GVHD was graded according to Glucksberg criteria and
Chronic Graft versus Host Disease was graded by NIH
consensus criteria. Statistical analysis: Kaplan Meier (sur-
vival) and Fisher test (comparison of categorical variables). P
level of signiﬁcance was <0.05.
Results: Thirty three percent of patients developed GVHD
(40 males and 24 females). Median age was 6 years old (1-
31). 61 patients received CBT from a mismatched donor.
Thirty (48%) were transplanted for malignancies. Five
transplants were from a related and 59 from an unrelateddonor. Conditioning: Reduced intensity (RIC) in 6 cases and
myeloablative in 58. Engraftment was complete in 48 cases
(75%). Median survival in group 1 was 1832d (27-7283)
versus 201d in group 2 (1-6242). Twenty nine patients have
died. Forty one patients developed acute GVHD (aGVHD), 6
patients classic chronic GVHD (cGVHD) and 17 had an over-
lap syndrome. Grade II-IV aGVHD was seen in 49 cases
(84.4%). Among cGVHD patients 9 (39.2%) were mild, 6 (26%)
moderate and 8 (34.8%) severe. Median time for the onset of
aGVHD was 23d (7-227) and cGVHD was 176d (64-659). The
main sites of aGVHD were skin: 55(86%), gut: 22 (34%) and
liver:14 (21%). Among cGVHD patients, 14 had skin (21%),
liver:12 (18%), mouth:9 (14%), gut and lung (BO): 6(9%) each.
Median time of cyclosporine therapy was 923d (7-3365).
Steroids were used for a median time of 290d (8-4303).
GVHD was less common in patients with a full match donor
(p¼0,001), those who used thymoglobuline (p<0,0001) and
methotrexate (MTX) (p¼0,0133). In contrast, GVHD rates
were higher in patients who had an early (p¼0,0111) and
complete (p<0,0001) engraftment and had bacterial
(p¼0,0133) or viral (p¼0,0086) infections during the pre-
engraftment time. Survival rates were higher in patients who
developed GVHD (p¼0,0256), had a myeloablative condi-
tioning regimen (p¼0,048), children <14 yo (p¼0,0002),
patients who used cyclosporine for at least one year
(p<0,0001) and full chimerism (p<0,0001).
Conclusions: We conclude GVHD can be frequent and even
serious in CBT recipients. Risk factors included early and
complete engraftment, mismatched donor, viral or bacterial
infection during the pre-engraftment period, use of RIC and
lack of MTX. Risk factors for survival were absence of GVHD,
RIC, older age, and lack of full engraftment.416
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Background: Acute graft-versus-host disease (GVHD) re-
mains a leading cause of morbidity and mortality in alloge-
neic hematopoietic stem cell transplant (HSCT) recipients.
